{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:07:49Z","timestamp":1784308069253,"version":"3.55.0"},"reference-count":153,"publisher":"Elsevier","isbn-type":[{"value":"9780443346811","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.ant.2026.03.001","type":"book-chapter","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:31:44Z","timestamp":1783974704000},"page":"129-163","source":"Crossref","is-referenced-by-count":0,"title":["Nutraceuticals and obsessive-compulsive disorder therapy"],"prefix":"10.1016","author":[{"given":"Amir Hossein","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed Abolfazl","family":"Tavousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood Khaksary","family":"Mahabady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Aschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0001","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","article-title":"N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Afshar","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/bs.ant.2026.03.001_bib0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/bs8080065","article-title":"Acute administration of caffeine: the effect on motor coordination, higher brain cognitive functions, and the social behavior of BLC57 mice","volume":"8","author":"Almosawi","year":"2018","journal-title":"Behav. Sci."},{"issue":"8","key":"10.1016\/bs.ant.2026.03.001_bib0003","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/0748233712462468","article-title":"Nutraceuticals of anti-inflammatory activity as complementary therapy for rheumatoid arthritis","volume":"30","author":"Al-Okbi","year":"2014","journal-title":"Toxicol. Ind. Health"},{"issue":"8 Suppl 2","key":"10.1016\/bs.ant.2026.03.001_bib0005","first-page":"9S","article-title":"Clinical practice guidelines. Management of anxiety disorders","volume":"51","author":"Association","year":"2006","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/bs.ant.2026.03.001_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.brat.2020.103697","article-title":"Temporal precedence of the change in obsessive-compulsive symptoms and change in depressive symptoms during exposure and response prevention for pediatric obsessive-compulsive disorders","volume":"133","author":"Bakhshaie","year":"2020","journal-title":"Behav. Res. Ther."},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0007","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1159\/000514075","article-title":"Serum vitamins and homocysteine levels in obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"80","author":"Balandeh","year":"2021","journal-title":"Neuropsychobiology"},{"issue":"S35","key":"10.1016\/bs.ant.2026.03.001_bib0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1192\/S0007125000297857","article-title":"Role of serotonin in obsessive-compulsive disorder","volume":"173","author":"Baumgarten","year":"1998","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/bs.ant.2026.03.001_bib0009","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.1992.01820090009002","article-title":"Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder","volume":"49","author":"Baxter","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"26","key":"10.1016\/bs.ant.2026.03.001_bib0010","doi-asserted-by":"crossref","first-page":"15730","DOI":"10.1073\/pnas.95.26.15730","article-title":"Modulation of N-methyl-D-aspartate receptor function by glycine transport","volume":"95","author":"Bergeron","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0011","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tips.2013.01.001","article-title":"The promise of N-acetylcysteine in neuropsychiatry","volume":"34","author":"Berk","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/bs.ant.2026.03.001_bib0012","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0013","doi-asserted-by":"crossref","first-page":"401","DOI":"10.31887\/DCNS.2011.13.4\/bboileau","article-title":"A review of obsessive-compulsive disorder in children and adolescents","volume":"13","author":"Boileau","year":"2011","journal-title":"Dialogues Clin. Neurosci."},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0014","doi-asserted-by":"crossref","first-page":"401","DOI":"10.31887\/DCNS.2011.13.4\/bboileau","article-title":"A review of obsessive-compulsive disorder in children and adolescents","volume":"13","author":"Boileau","year":"2011","journal-title":"Dialogues Clin. Neurosci."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1227\/NEU.0b013e31827b9c7c","article-title":"Beneficial effect of subsequent lesion procedures after nonresponse to initial cingulotomy for severe, treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bourne","year":"2013","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0016","first-page":"3","article-title":"Between religion and science some aspects concerning illness and healing in antiquity","volume":"24","author":"Bung\u00e3u","year":"2015","journal-title":"Transylv. Rev."},{"issue":"5","key":"10.1016\/bs.ant.2026.03.001_bib0017","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1369\/jhc.5A6840.2006","article-title":"Distribution of the cystine\/glutamate antiporter system x\u2212 c in the brain, kidney, and duodenum","volume":"54","author":"Burdo","year":"2006","journal-title":"J. Histochem. Cytochem."},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0018","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.pnpbp.2011.02.011","article-title":"Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence","volume":"35","author":"Camfield","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"12","key":"10.1016\/bs.ant.2026.03.001_bib0019","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.biopsych.2004.09.029","article-title":"Amygdala responses to human faces in obsessive-compulsive disorder","volume":"56","author":"Cannistraro","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0020","first-page":"203","article-title":"The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems","volume":"28","author":"Carabotti","year":"2015","journal-title":"Ann. gastroenterol. Q. Publ. Hell. Soc. Gastroenterol."},{"issue":"11","key":"10.1016\/bs.ant.2026.03.001_bib0021","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3390\/nu9111247","article-title":"Probiotic, prebiotic, and brain development","volume":"9","author":"Cerd\u00f3","year":"2017","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/bs.ant.2026.03.001_bib0022","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1753-4887.2012.00484.x","article-title":"Nutraceuticals and their preventive or potential therapeutic value in Parkinson\u2019s disease","volume":"70","author":"Chao","year":"2012","journal-title":"Nutr. Rev."},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0023","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrn1078","article-title":"Neurotrophins and their receptors: a convergence point for many signalling pathways","volume":"4","author":"Chao","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1152\/jn.00342.2002","article-title":"Evidence for functionally distinct synaptic NMDA receptors in ventromedial versus dorsolateral striatum","volume":"89","author":"Chapman","year":"2003","journal-title":"J. Neurophysiol."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0025","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1152\/jn.00680.2002","article-title":"Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo","volume":"89","author":"Chen","year":"2003","journal-title":"J. Neurophysiol."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0026","first-page":"81","article-title":"Effect of curcumin on quinpirole induced compulsive checking: an approach to determine the predictive and construct validity of the model","volume":"2","author":"Chimakurthy","year":"2010","journal-title":"N. Am. J. Med. Sci."},{"issue":"21","key":"10.1016\/bs.ant.2026.03.001_bib0027","doi-asserted-by":"crossref","first-page":"13675","DOI":"10.1073\/pnas.182412499","article-title":"Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia","volume":"99","author":"Chumakov","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/bs.ant.2026.03.001_bib0028","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.physbeh.2016.12.031","article-title":"Caffeine stimulates voluntary wheel running in mice without increasing aerobic capacity","volume":"170","author":"Claghorn","year":"2017","journal-title":"Physiol. Behav."},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0029","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4088\/JCP.15m10278","article-title":"The economic burden of schizophrenia in the United States in 2013","volume":"77","author":"Cloutier","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.clindermatol.2008.01.010","article-title":"Antioxidant use in nutraceuticals","volume":"27","author":"Cornelli","year":"2009","journal-title":"Clin. Dermatol."},{"issue":"7","key":"10.1016\/bs.ant.2026.03.001_bib0031","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.4088\/JCP.16m11101","article-title":"Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"78","author":"Costa","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/bs.ant.2026.03.001_bib0032","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1054-3589(08)60985-0","article-title":"N-acetylcystei ne: pharmacological considerations and experimental and clinical applications","volume":"38","author":"Cotgreave","year":"1996","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/bs.ant.2026.03.001_bib0033","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pnpbp.2018.06.005","article-title":"Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: a systematic review of the clinical evidence","volume":"86","author":"Couto","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/bs.ant.2026.03.001_bib0034","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pnpbp.2018.06.005","article-title":"Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: a systematic review of the clinical evidence","volume":"86","author":"Couto","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/0269881107079865","article-title":"Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series","volume":"22","author":"Dell\u2019Osso","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0036","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/1541-4337.12547","article-title":"Bioavailability of nutraceuticals: role of the food matrix, processing conditions, the gastrointestinal tract, and nanodelivery systems","volume":"19","author":"Dima","year":"2020","journal-title":"Compr. Rev. Food Sci. Food Saf."},{"issue":"9","key":"10.1016\/bs.ant.2026.03.001_bib0037","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/nmo.12198","article-title":"Melancholic microbes: a link between gut microbiota and depression?","volume":"25","author":"Dinan","year":"2013","journal-title":"Neurogastroenterol. Motil."},{"issue":"7","key":"10.1016\/bs.ant.2026.03.001_bib0038","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/FBP.0b013e328358477c","article-title":"Increased serotonergic neurotransmission is not responsible for the anticompulsive effect of berberine in a murine model of obsessive\u2013compulsive disorder","volume":"23","author":"Dixit","year":"2012","journal-title":"Behav. Pharmacol."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0039","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1176\/appi.ajp.159.2.269","article-title":"Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder","volume":"159","author":"Dougherty","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/bs.ant.2026.03.001_bib0041","first-page":"723","article-title":"Diagnostic and statistical manual of mental disorders","volume":"30","author":"Edition","year":"2013","journal-title":"Depr. Anxi."},{"issue":"8","key":"10.1016\/bs.ant.2026.03.001_bib0042","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/da.22132","article-title":"Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy","volume":"30","author":"Farrell","year":"2013","journal-title":"Depress Anxiety"},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0043","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/da.23242","article-title":"Efficacy of D-cycloserine augmented brief intensive cognitive-behavioural therapy for paediatric obsessive-compulsive disorder: a randomised clinical trial","volume":"39","author":"Farrell","year":"2022","journal-title":"Depress Anxiety"},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0044","first-page":"239","article-title":"Obsessive compulsive disorder: diagnosis and management","volume":"80","author":"Fenske","year":"2009","journal-title":"Am. Fam. Physician"},{"issue":"8","key":"10.1016\/bs.ant.2026.03.001_bib0045","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1017\/S1461145711001829","article-title":"Evidence-based pharmacotherapy of obsessive-compulsive disorder","volume":"15","author":"Fineberg","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0046","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145704004675","article-title":"Evidence-based pharmacotherapy of obsessive\u2013compulsive disorder","volume":"8","author":"Fineberg","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0047","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/YIC.0b013e32825ea312","article-title":"Sustained response versus relapse: the pharmacotherapeutic goal for obsessive\u2013compulsive disorder","volume":"22","author":"Fineberg","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0048","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0031-6997(24)01396-6","article-title":"Actions of caffeine in the brain with special reference to factors that contribute to its widespread use","volume":"51","author":"Fredholm","year":"1999","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0049","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S1461145799001546","article-title":"Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study","volume":"2","author":"Fux","year":"1999","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3956(03)00077-3","article-title":"A placebo-controlled cross-over trial of adjunctive EPA in OCD","volume":"38","author":"Fux","year":"2004","journal-title":"J. Psychiatr. Res."},{"issue":"9","key":"10.1016\/bs.ant.2026.03.001_bib0051","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1176\/ajp.153.9.1219","article-title":"Inositol treatment of obsessive-compulsive disorder","volume":"153","author":"Fux","year":"1996","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0052","first-page":"134","article-title":"Efficacy of N-acetylcysteine augmentation on obsessive compulsive disorder: a multicenter randomized double blind placebo controlled clinical trial","volume":"12","author":"Ghanizadeh","year":"2017","journal-title":"Iran J. Psychiatry"},{"key":"10.1016\/bs.ant.2026.03.001_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173652","article-title":"Multistrain probiotic rescinds quinpirole-induced obsessive-compulsive disorder phenotypes by reshaping of microbiota gut-brain axis in rats","volume":"232","author":"Ghuge","year":"2023","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/bs.ant.2026.03.001_bib0054","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.copbio.2014.01.010","article-title":"Bioactive fungal polysaccharides as potential functional ingredients in food and nutraceuticals","volume":"26","author":"Giavasis","year":"2014","journal-title":"Curr. Opin. Biotechnol."},{"issue":"7-8","key":"10.1016\/bs.ant.2026.03.001_bib0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.drudis.2007.12.009","article-title":"Serotoninergic mechanisms in the treatment of obsessive\u2013compulsive disorder","volume":"13","author":"Goddard","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/bs.ant.2026.03.001_bib0056","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-med-052209-100401","article-title":"Deep brain stimulation for intractable psychiatric disorders","volume":"63","author":"Goodman","year":"2012","journal-title":"Annu. Rev. Med."},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0057","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jpsychires.2008.10.007","article-title":"Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults","volume":"43","author":"Greenberg","year":"2009","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0058","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijantimicag.2018.04.024","article-title":"Plant nutraceuticals as antimicrobial agents in food preservation: terpenoids, polyphenols and thiols","volume":"52","author":"Guti\u00e9rrez-del-R\u00edo","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0059","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.beth.2020.11.001","article-title":"Irritability in children and adolescents with OCD","volume":"52","author":"Guzick","year":"2021","journal-title":"Behav. Ther."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0060","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/npp.2012.182","article-title":"Translational research in OCD: circuitry and mechanisms","volume":"38","author":"Haber","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0061","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0924-977X(02)00129-3","article-title":"Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder","volume":"13","author":"Hemmings","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0062","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1176\/jnp.2008.20.4.390","article-title":"A psychological and neuroanatomical model of obsessive-compulsive disorder","volume":"20","author":"Huey","year":"2008","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/bs.ant.2026.03.001_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.afnr.2016.12.008","article-title":"Nanotechnology approaches for increasing nutrient bioavailability","volume":"81","author":"Jafari","year":"2017","journal-title":"Adv. Food. Nutr. Res."},{"issue":"5","key":"10.1016\/bs.ant.2026.03.001_bib0064","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.freeradbiomed.2007.11.011","article-title":"Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson\u2019s disease explained via in silico studies","volume":"44","author":"Jagatha","year":"2008","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1208\/ps050325","article-title":"Nutraceutical-definition and introduction","volume":"5","author":"Kalra","year":"2003","journal-title":"Aaps Pharmsci."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0066","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/FBP.0000000000000013","article-title":"Obsessive\u2013compulsive-like behaviors in house mice are attenuated by a probiotic (Lactobacillus rhamnosus GG)","volume":"25","author":"Kantak","year":"2014","journal-title":"Behav. Pharmacol."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0067","article-title":"Nutritional and herbal supplements in the treatment of obsessive compulsive disorder","volume":"33","author":"Karc\u0131","year":"2020","journal-title":"Gen. Psychiatry"},{"key":"10.1016\/bs.ant.2026.03.001_bib0068","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.tifs.2017.07.017","article-title":"Formulation and application of a new generation of lipid nano-carriers for the food bioactive ingredients","volume":"68","author":"Katouzian","year":"2017","journal-title":"Trends Food Sci. Technol."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0069","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.neuroscience.2008.06.010","article-title":"Blunted cystine\u2013glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking","volume":"155","author":"Kau","year":"2008","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0070","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.neubiorev.2011.07.001","article-title":"Gut memories: towards a cognitive neurobiology of irritable bowel syndrome","volume":"36","author":"Kennedy","year":"2012","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0071","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41430-018-0135-9","article-title":"A review of probiotic supplementation in healthy adults: helpful or hype?","volume":"73","author":"Khalesi","year":"2019","journal-title":"Eur. J. Clin. Nutr."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0072","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbrc.2012.12.121","article-title":"Lactobacillus rhamnosus GG improves insulin sensitivity and reduces adiposity in high-fat diet-fed mice through enhancement of adiponectin production","volume":"431","author":"Kim","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0073","first-page":"275","article-title":"Second-generation antipsychotics for obsessive compulsive disorder","volume":"10","author":"Komossa","year":"2010","journal-title":"Expert Rev. Neurother."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0074","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/ern.09.148","article-title":"Role of dopamine in the pathophysiology and treatment of obsessive\u2013compulsive disorder","volume":"10","author":"Koo","year":"2010","journal-title":"Expert. Rev. Neurother."},{"issue":"11","key":"10.1016\/bs.ant.2026.03.001_bib0075","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.4088\/JCP.08m04605","article-title":"Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"70","author":"Koran","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0076","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4088\/JCP.v66n0415","article-title":"Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation","volume":"66","author":"Koran","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/bs.ant.2026.03.001_bib0004","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Koran Am. J. Psychiatry."},{"issue":"7 Suppl","key":"10.1016\/bs.ant.2026.03.001_bib0077","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/bs.ant.2026.03.001_bib0078","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pneurobio.2004.03.006","article-title":"The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology","volume":"72","author":"Kringelbach","year":"2004","journal-title":"Prog. Neurobiol."},{"issue":"8","key":"10.1016\/bs.ant.2026.03.001_bib0079","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13249","article-title":"Effect of D-Cycloserine on the effect of concentrated exposure and response prevention in difficult-to-treat obsessive-compulsive disorder: a randomized clinical trial","volume":"3","author":"Kvale","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0080","first-page":"61","article-title":"The gut microbiota in internal medicine: implications for health and disease","volume":"73","author":"Lankelma","year":"2015","journal-title":"Neth. J. Med."},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0081","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/da.20669","article-title":"Obsessive\u2013compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V","volume":"27","author":"Leckman","year":"2010","journal-title":"Depress. Anxiety"},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0082","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/cap.2019.0041","article-title":"N-acetylcysteine for pediatric obsessive-compulsive disorder: a small pilot study","volume":"30","author":"Li","year":"2020","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"issue":"12","key":"10.1016\/bs.ant.2026.03.001_bib0083","first-page":"4424","article-title":"OCD: serotonergic mechanisms","volume":"21","author":"Lissemore","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/bs.ant.2026.03.001_bib0084","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.3390\/ijms21124424","article-title":"Nutraceuticals in neurological disorders","volume":"21","author":"Makkar","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4-5","key":"10.1016\/bs.ant.2026.03.001_bib0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s007020050064","article-title":"Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone","volume":"105","author":"Martin","year":"1998","journal-title":"J. Neural. Transm."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0086","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0006-8993(00)02646-9","article-title":"Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette\u2019s syndrome and obsessive\u2013compulsive disorder","volume":"877","author":"McGrath","year":"2000","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0087","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1192\/bjp.164.4.459","article-title":"Functional anatomy of obsessive\u2013compulsive phenomena","volume":"164","author":"McGuire","year":"1994","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0088","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4103\/1735-5362.199046","article-title":"Effect of concomitant administration of three different antidepressants with vitamin B6 on depression and obsessive compulsive disorder in mice models","volume":"12","author":"Mesripour","year":"2017","journal-title":"Res. Pharm. Sci."},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0089","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4274\/tjps.galenos.2019.94210","article-title":"A synbiotic mixture augmented the efficacy of doxepin, venlafaxine, and fluvoxamine in a mouse model of depression","volume":"17","author":"Mesripour","year":"2020","journal-title":"Turk. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0090","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/gmic.2.4.16108","article-title":"Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers","volume":"2","author":"Messaoudi","year":"2011","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0091","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tics.2011.11.003","article-title":"Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways","volume":"16","author":"Milad","year":"2012","journal-title":"Trends Cogn. Sci."},{"issue":"10","key":"10.1016\/bs.ant.2026.03.001_bib0092","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2174\/1871527320666210506185510","article-title":"Magic shotgun nature with scattergun approach of curcumin repurposing in obsessive-compulsive disorder: a novel metaphysician of drug discovery","volume":"20","author":"Mishra","year":"2021","journal-title":"CNS Neurol. Disord. Drug Targets-CNS Neurol. Disord."},{"issue":"7","key":"10.1016\/bs.ant.2026.03.001_bib0040","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/FBP.0000000000000570","article-title":"Trait specific modulatory effects of caffeine exposure on compulsive-like behaviors in a spontaneous mouse model of obsessive-compulsive disorder","volume":"31","author":"Mitra","year":"2020","journal-title":"Behav. Pharmacol."},{"issue":"7","key":"10.1016\/bs.ant.2026.03.001_bib0093","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/FBP.0000000000000570","article-title":"Trait specific modulatory effects of caffeine exposure on compulsive-like behaviors in a spontaneous mouse model of obsessive-compulsive disorder","volume":"31","author":"Mitra","year":"2020","journal-title":"Behav. Pharmacol."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0094","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12991-021-00354-2","article-title":"Malondialdehyde concentrations in obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"20","author":"Mohammadi","year":"2021","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/bs.ant.2026.03.001_bib0110a","doi-asserted-by":"crossref","unstructured":"Mohammadi, A. H., Karimian, M., Mirzaei, H., and Milajerdi, A., 2023. Epigenetic modifications and obsessive--compulsive disorder: what do we know? Brain Structure and Function, 228 (5), 1295--1305.","DOI":"10.1007\/s00429-023-02649-4"},{"key":"10.1016\/bs.ant.2026.03.001_bib0110b","doi-asserted-by":"crossref","unstructured":"Mohammadi, A. H., Balandeh, E., Hasani, J., Karimian, M., Arabshahi, V., Pourfarzam, M., et al. (2024). The oxidative status and Na+\/K+-ATPase activity in obsessive-compulsive disorder: a case-control study. BioMed Res. Int. 2024 (1), 9979582.","DOI":"10.1155\/2024\/9979582"},{"issue":"5","key":"10.1016\/bs.ant.2026.03.001_bib0095","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.euroneuro.2008.12.009","article-title":"Behavioral changes in G72\/G30 transgenic mice","volume":"19","author":"Otte","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0096","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1111\/j.1750-3841.2007.00274.x","article-title":"Food microstructure affects the bioavailability of several nutrients","volume":"72","author":"Parada","year":"2007","journal-title":"J. Food Sci."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0097","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrn3379","article-title":"Neurotrophin regulation of neural circuit development and function","volume":"14","author":"Park","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0098","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrn3746","article-title":"Obsessive\u2013compulsive disorder: an integrative genetic and neurobiological perspective","volume":"15","author":"Pauls","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0099","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jcpt.12370","article-title":"N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial","volume":"41","author":"Paydary","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0100","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1192\/bjp.166.2.244","article-title":"[18F] FDG PET study in obsessive\u2013compulsive disorder: a clinical\/metabolic correlation study after treatment","volume":"166","author":"Perani","year":"1995","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0101","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1515\/jbcpp-2017-0155","article-title":"Improved serotonergic neurotransmission by genistein pretreatment regulates symptoms of obsessive-compulsive disorder in streptozotocin-induced diabetic mice","volume":"29","author":"Phadnis","year":"2018","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0102","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","volume":"132","author":"Pittenger","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0103","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment","volume":"132","author":"Pittenger","year":"2011","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0104","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/glia.1037","article-title":"Visualising the activity of the cystine-glutamate antiporter in glial cells using antibodies to aminoadipic acid, a selectively transported substrate","volume":"34","author":"Pow","year":"2001","journal-title":"Glia"},{"key":"10.1016\/bs.ant.2026.03.001_bib0105","series-title":"Ensuring Global Food Safety: Exploring Global Harmonization","first-page":"333","article-title":"Nutraceuticals: possible future ingredients and food safety aspects","author":"Prakash","year":"2010"},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0106","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1017\/S1461145705005341","article-title":"Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD)\u2013the spontaneously hypertensive rat (SHR)","volume":"8","author":"Prediger","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/bs.ant.2026.03.001_bib0107","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archgenpsychiatry.2010.70","article-title":"Meta-analytical comparison of voxel-based morphometry studies in obsessive-compulsive disorder vs other anxiety disorders","volume":"67","author":"Radua","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/bs.ant.2026.03.001_bib0108","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tifs.2019.04.017","article-title":"Application of curcumin-loaded nanocarriers for food, drug and cosmetic purposes","volume":"88","author":"Rafiee","year":"2019","journal-title":"Trends Food Sci. Technol."},{"key":"10.1016\/bs.ant.2026.03.001_bib0109","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tifs.2019.04.017","article-title":"Application of curcumin-loaded nanocarriers for food, drug and cosmetic purposes","volume":"88","author":"Rafiee","year":"2019","journal-title":"Trends Food Sci. Technol."},{"key":"10.1016\/bs.ant.2026.03.001_bib0110","article-title":"The therapeutic potential of medicinal foods","volume":"2014","author":"Ramalingum","year":"2014","journal-title":"Adv. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0111","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.1994.03950010062008","article-title":"Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography","volume":"51","author":"Rauch","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0112","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.biopsych.2005.12.012","article-title":"Functional magnetic resonance imaging study of regional brain activation during implicit sequence learning in obsessive\u2013compulsive disorder","volume":"61","author":"Rauch","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.ant.2026.03.001_bib0113","article-title":"Symptom trajectories of early responders and remitters among youth with OCD","volume":"27","author":"Rech","year":"2020","journal-title":"J. Obs. Compuls. Relat. Disord."},{"key":"10.1016\/bs.ant.2026.03.001_bib0114","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2019.02.005","article-title":"Nanoencapsulation of carotenoids within lipid-based nanocarriers","volume":"298","author":"Rostamabadi","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0116","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0117","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s12602-020-09642-x","article-title":"The Effect of Lactobacillus casei consumption in improvement of obsessive\u2013compulsive disorder: an animal study","volume":"12","author":"Sanikhani","year":"2020","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"10.1016\/bs.ant.2026.03.001_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110550","article-title":"N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: a phase III, 20-week, double-blind, randomized, placebo-controlled trial","volume":"117","author":"Sarris","year":"2022","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/bs.ant.2026.03.001_bib0119","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1017\/S1092852921000638","article-title":"Treatment of refractory obsessive-compulsive disorder with nutraceuticals (TRON): a 20-week, open label pilot study","volume":"27","author":"Sarris","year":"2022","journal-title":"CNS Spectr."},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0120","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1177\/2167702616639864","article-title":"Participant characteristics as modifiers of response to N-acetyl cysteine (NAc) in obsessive-compulsive disorder","volume":"4","author":"Sarris","year":"2016","journal-title":"Clin. Psychol. Sci."},{"issue":"9","key":"10.1016\/bs.ant.2026.03.001_bib0121","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40263-015-0272-9","article-title":"N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: A 16-week, double-blind, randomised, placebo-controlled study","volume":"29","author":"Sarris","year":"2015","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0122","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0193-953X(05)70181-7","article-title":"Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder","volume":"23","author":"Saxena","year":"2000","journal-title":"Psychiatr. Clin. North Am."},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0123","doi-asserted-by":"crossref","first-page":"57","DOI":"10.12740\/APP\/99584","article-title":"Effect of selenium as an adjunctive therapy in patients with treatment-resistant obsessive-compulsive disorder: a pilot randomized double blind placebo-controlled clinical trial","volume":"20","author":"Sayyah","year":"2018","journal-title":"Arch. Psych. Psych."},{"issue":"9","key":"10.1016\/bs.ant.2026.03.001_bib0124","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.nut.2011.11.027","article-title":"Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: a randomized placebo-controlled clinical trial","volume":"28","author":"Sayyah","year":"2012","journal-title":"Nutrition"},{"issue":"12","key":"10.1016\/bs.ant.2026.03.001_bib0125","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/hbm.20980","article-title":"Fronto-cingulate effective connectivity in obsessive compulsive disorder: a study with fMRI and dynamic causal modeling","volume":"31","author":"Schl\u00f6sser","year":"2010","journal-title":"Hum. Brain Mapp."},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0126","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004850-199911000-00005","article-title":"Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial","volume":"14","author":"Seedat","year":"1999","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/bs.ant.2026.03.001_bib0127","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.4103\/jfmpc.jfmpc_93_19","article-title":"Using caffeine on the patients as therapeutic option against treatment-resistant obsessive-compulsive disorder","volume":"8","author":"Shams","year":"2019","journal-title":"J. Fam. Med. Prim. Care"},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/0884533608329231","article-title":"Unraveling mechanisms of action of probiotics","volume":"24","author":"Sherman","year":"2009","journal-title":"Nutr. Clin. Pr."},{"issue":"Suppl 1","key":"10.1016\/bs.ant.2026.03.001_bib0129","first-page":"S58","article-title":"Glutamatergic augmentation strategies in obsessive\u2013compulsive disorder","volume":"61","author":"Sheshachala","year":"2019","journal-title":"Indian J. Psychiatry"},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0130","first-page":"728","article-title":"Fronto-striato-limbic hyperactivation in obsessive-compulsive disorder during individually tailored symptom provocation","volume":"47","author":"Simon","year":"2010","journal-title":"Psychophysiology"},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0131","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4088\/JCP.v67n0214","article-title":"Response versus remission in obsessive-compulsive disorder","volume":"67","author":"Simpson","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/bs.ant.2026.03.001_bib0132","series-title":"Martin\u2019s physical pharmacy and pharmaceutical sciences: physical chemical and biopharmaceutical principles in the pharmaceutical sciences","year":"2024"},{"issue":"9","key":"10.1016\/bs.ant.2026.03.001_bib0133","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0278-6915(02)00096-0","article-title":"Effects of caffeine on human behavior","volume":"40","author":"Smith","year":"2002","journal-title":"Food Chem. Toxicol."},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0134","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)","volume":"2008","author":"Soomro","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/YIC.0b013e32819f8480","article-title":"D-cycloserine does not enhance exposure\u2013response prevention therapy in obsessive\u2013compulsive disorder","volume":"22","author":"Storch","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/bs.ant.2026.03.001_bib0136","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.biopsych.2010.07.015","article-title":"A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder","volume":"68","author":"Storch","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/bs.ant.2026.03.001_bib0137","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/archpsyc.1992.01820090018003","article-title":"Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder: revisualization during pharmacotherapy","volume":"49","author":"Swedo","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0138","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1037\/0735-7044.112.6.1475","article-title":"Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD)","volume":"112","author":"Szechtman","year":"1998","journal-title":"Behav. Neurosci."},{"key":"10.1016\/bs.ant.2026.03.001_bib0139","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fpsyt.2017.00080","article-title":"The safety of ingested caffeine: a comprehensive review","volume":"8","author":"Temple","year":"2017","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/bs.ant.2026.03.001_bib0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.24869\/psyd.2019.69","article-title":"Double blind controlled study of adding folic acid to fluoxetine in the treatment of OCD","volume":"31","author":"Tural","year":"2019","journal-title":"Psychiatr. Danub."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0142","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4067\/S0716-97602000000200004","article-title":"Plant polyphenol antioxidants and oxidative stress","volume":"33","author":"Urquiaga","year":"2000","journal-title":"Biol. Res."},{"key":"10.1016\/bs.ant.2026.03.001_bib0141","unstructured":"U.S. Food and Drug Administration, 2012. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related-potential. (accessed 20 June 2026)."},{"issue":"2","key":"10.1016\/bs.ant.2026.03.001_bib0143","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00253-006-0818-3","article-title":"Synergistic effects of Lactobacillus rhamnosus ZDY114 and bovine colostrums on the immunological function of mouse in vivo and in vitro","volume":"75","author":"Wei","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0144","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1037\/a0013076","article-title":"Group and individual treatment of obsessive-compulsive disorder using cognitive therapy and exposure plus response prevention: a 2-year follow-up of two randomized trials","volume":"76","author":"Whittal","year":"2008","journal-title":"J. Consult. Clin. Psychol."},{"issue":"4","key":"10.1016\/bs.ant.2026.03.001_bib0145","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.pbb.2011.10.007","article-title":"The role of glutamate signaling in the pathogenesis and treatment of obsessive\u2013compulsive disorder","volume":"100","author":"Wu","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3","key":"10.1016\/bs.ant.2026.03.001_bib0146","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/JCP.0b013e3182189878","article-title":"Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study","volume":"31","author":"Wu","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/bs.ant.2026.03.001_bib0147","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/sj.bjp.0703170","article-title":"The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A2A receptors","volume":"129","author":"Yacoubi","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/bs.ant.2026.03.001_bib0148","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3389\/fnins.2019.01361","article-title":"Antidepressive mechanisms of probiotics and their therapeutic potential","volume":"13","author":"Yong","year":"2019","journal-title":"Front. Neurosci."},{"issue":"1-2","key":"10.1016\/bs.ant.2026.03.001_bib0149","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0378-8741(02)00211-8","article-title":"Antidepressant activity of aqueous extracts of Curcuma longa in mice","volume":"83","author":"Yu","year":"2002","journal-title":"J. Ethnopharmacol."},{"issue":"6","key":"10.1016\/bs.ant.2026.03.001_bib0150","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/00207454.2019.1684276","article-title":"Effects of glutamate-related drugs on anxiety and compulsive behavior in rats with obsessive-compulsive disorder","volume":"130","author":"Zhan","year":"2020","journal-title":"Int. J. Neurosci."},{"issue":"13","key":"10.1016\/bs.ant.2026.03.001_bib0151","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1113\/jphysiol.2009.168757","article-title":"The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine","volume":"587","author":"Zhang","year":"2009","journal-title":"J. Physiol."}],"container-title":["Advances in Neurotoxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468748026000081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468748026000081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:33:43Z","timestamp":1784306023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468748026000081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443346811"],"references-count":153,"URL":"https:\/\/doi.org\/10.1016\/bs.ant.2026.03.001","relation":{},"ISSN":["2468-7480"],"issn-type":[{"value":"2468-7480","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}